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A B S T R A C T
The utilization and prescribing quality of non-steroidal anti-inflammatory drugs (NSAIDs) in Zagreb were as-
sessed by calculating the number of defined daily doses (DDDs) from the number and size of packages of each prescrip-
tion NSAID dispensed at 31 and 32 pharmacies during the years 2001 and 2002. NSAIDs accounting for 95% of over-
all NSAID utilization (DU95% segment) were analyzed. The proportion of NSAIDs associated with high (piroxicam),
medium (diclofenac, naproxen, indometacin and ketoprofen) and low (ibuprofen) risk of gastrointestinal side effects,
cost for each NSAID in DU95% segment, and cost per DDD were calculated. Four NSAIDs fell within DU95% segment:
ibuprofen, diclofenac, ketoprofen and piroxicam. The cost for NSAIDs per DDD was by half lower within than beyond
DU95% segment. Piroxicam was most expensive, and diclofenac and ketoprofen least expensive NSAIDs within
DU95% in 2001 and 2002, respectively. The NSAID prescribing pattern was found to be in discrepancy with their rela-
tive gastrointestinal toxicity.
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Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
a group of drugs that are most commonly used as anal-
gesics, anti-inflammatory agents or antipyretics. The
wide use of these drugs results in gastrointestinal (GI)
complications, which are the main cause of morbidity
and mortality associated with this type of therapy1,2.
The risk of GI complications shows several-fold varia-
tion and dose dependence among NSAIDs3,4. In addition
to patient risk, these drugs also rank high according to
the rate of hospitalization1,5,6, thus causing high total
costs for both NSAIDs and treatment of GI compli-
cations7–9. In order to reduce the morbidity and costs as-
sociated with the use of NSAIDs, the utilization and
quality of prescribing these drugs should first be evalu-
ated. With this objective in mind, we embarked upon
this study in the City of Zagreb, the capital of Croatia,
with some 25% of the population of Croatia living in and
around Zagreb, and 43% of the national health re-
sources being located in the area. Study results were
evaluated in comparison with those reported from other
capitals in Europe.
Materials and Methods
Data on the number and size of packages of each in-
dividual NSAID dispensed at 32 and 31 pharmacies
evenly distributed all over the City of Zagreb were ob-
tained from the Zagreb Municipal Pharmacy owned by
the state. These pharmacies represented a sample (16%
in 2001 and 15% in 2002, respectively) of the total num-
ber of pharmacies registered in the City of Zagreb. The
data were exclusively collected for prescription drugs in
oral dosage form and referred to the years 2001 and
2002.
The number of defined daily doses (DDDs) for each
NSAID was calculated from the collected data classified
according to the Anatomical Therapeutic Chemical Sys-
tem (ATC) of the World Health Organization (WHO)
and DDDs for NSAIDs listed in the ATC Index with
DDDs 2002. Then, each NSAID (ATC: M01A) was ran-
ked according to DDD number to restrict our studies to
those NSAIDs which accounted for 95% of total NSAID
utilization, i.e. to the drug utilization 95% segment.
This method is identical to that of Bergman et al10,
which has recently been introduced for assessing the
quality of drug prescribing and usage. Within the drug
utilization (DU95%) segment, we determined the pro-
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portion of high risk (piroxicam), medium risk (diclo-
fenac, naproxen, indometacin and ketoprofen) and low
risk (ibuprofen) NSAIDs with respect to the risk of up-
per GI bleeding/perforation (UGIB)4. The remaining
drugs were categorized as unclassified due to the lack of
epidemiologic GI safety data (meloxicam, nabumetone,
tenoxicam) and ambiguities about the safety profile
(rofecoxib)11.
DU95% segment was determined for the years 2001
and 2002 according to DDD number for each NSAID
and overall DDD number for all NSAIDs in DU95%.
Costs for each individual NSAID in DU95% were calcu-
lated. In addition, the cost per DDD for each NSAID in
DU95% segment, mean total cost per DDD for all NSAIDs
within and beyond DU95% segment, and mean cost per
DDD for all NSAIDs dispensed at Zagreb Municipal
Pharmacy units during 2001 and 2002 were also calcu-
lated. The price of NSAIDs was uniform in all pharma-
cies.
I. Vuku{i} et al.: Cost-Efficiency of NSAID Prescribing in Croatia, Coll. Antropol. 29 (2005) 1: 143–147
144
Fig. 1. NSAID prescribing pattern in Zagreb according to number of defined daily doses (DDDs) based on
dispensing data from 32 Zagreb pharmacies in 2001.
Fig. 2. NSAID prescribing pattern in Zagreb according to number of defined daily doses (DDDs) based on
dispensing data from 31 Zagreb pharmacies in 2002.
TABLE 1
UTILIZATION OF NONSTEROIDAL ANTI-INFLAMMATORY
DRUGS (NSAIDS) IN ZAGREB EXPRESSED AS NUMBER OF
DEFINED DAILY DOSES (DDDS)
Drug name
DDDs Share (%)
2001 2001 2001 2002
Diclofenac 2126602 2004742 53.3 52.3
Piroxicam 714240 617800 17.9 16.1
Ketoprofen 583491 698560 14.6 18.2








Total 1–10 4258977 4029616
* The number of NSAIDs that accounts for 95% of NSAID use
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Results
Four of the ten NSAIDs fell within DU95% segment
according to their utilization in 2001 and 2002, respec-
tively (Figures 1 and 2). The absence of nabumetone
from the market was the only change recorded in 2002
as compared with 2001. Ibuprofen accounted for only
14.2% and 13.4% whereas diclofenac and ketoprofen ac-
counted for 67.9% and 70.5% in 2001 and 2002 respec-
tively. The respective figures for the high risk piroxicam
as the fourth drug in DU95% segment were 17.9% and
16.1% (Table 1). The leading drug in DU95% segment
was diclofenac accounting for 53.3% and 52.3% of
DU95% segment in 2001 and 2002, respectively.
Table 2 shows costs for each individual NSAID in
DU95% segment, overall costs for NSAIDs within and
beyond DU95% segment, and total costs for all NSAIDs.
In addition to absolute amounts, the proportion for each
drug within DU95% and cost per DDD for each drug in
DU95% segment, mean cost per DDD for drugs within
and beyond DU95% segment, and mean cost per DDD
for all NSAIDs on the market are presented for 2001
and 2002. The respective costs for NSAIDs in DU95%
segment accounted for 88.3% and 90.0% of total cost for
all NSAIDs on the market. The medium risk drugs in
DU95% segment accounted for 57.4% and 60.4%, the
low risk ibuprofen for 17.0% and 16.3%, and the high
risk piroxicam for 25.6% and 23.3% of the cost in DU95%
segment in 2001 and 2002, respectively. The mean cost
per DDD for NSAIDs in DU95% was half those beyond
DU95% segment. Piroxicam was the most expensive
NSAID in DU95% (0.27 and 0.26 EUR/DDD in 2001 and
2002, respectively), whereas least expensive ones were
diclofenac and ketoprofen (0.15 and 0.16 EUR/DDD,
and 0.18 and 0.14 EUR/DDD in 2001 and 2002, respec-
tively). Ketoprofen was the only drug showing a consid-
erable decline in the cost per DDD (from 0.18 EUR in
2001 to 0.14 EUR in 2002).
Discussion
Cost-efficiency of prescribing NSAIDs in the City of
Zagreb in 2001 and 2002 were assessed by identifying
the type and number of NSAIDs accounting for 95% of
total NSAID utilization, and ranking them according to
GI complications based on the systematic review of
case-control and cohort studies of serious GI complica-
tions and nonaspirin NSAIDs published between 1990
and 19994 although it seems difficult to sort them ac-
cording to their GI toxicity3,12,13. However the perti-
nence of the cost-analysis remain. Comparison of the
prescribing pattern in Zagreb with that reported from
other European cities and from Rijeka in Croatia14,15 re-
vealed a similar pattern with Rijeka but considerable
differences from other European cities or area (Table 3).
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TABLE 2
COST OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN ZAGREB EXPRESSED IN EUR, PERCENTAGE IN 2001 AND 2002,
AND COST PER DEFINED DAILY DOSE (DDD)
Drug name
Cost (Euro) Share (%) Cost/DDD (Euro)
2001 2002 2001 2002 2001 2002
Diclofenac 320507 323047 43.1 46.1 0.15 0.16
Piroxicam 190217 162783 25.6 23.3 0.27 0.26
Ketoprofen 106470 100008 14.3 14.3 0.18 0.14











Total 1–10 841576 778163 0.20 0.19
*The number of NSAIDs that accounts for 95% of NSAID use
TABLE 3
PRESCRIBING PROFILE FOR NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) IN EUROPEAN CITIES AND FUNEN,
DENMARK, RANKED BY NUMBER OF DEFINED DAILY DOSES (DDD)
City or area
Rank of NSAID
Ibuprofen Diclofenac Naproxen Indometacin Ketoprofen Piroxicam
Zagreba 4 1 8 6 2 3
Rijekab 3 1 – 5 6 2
Stockholmb 6 1 2 9 4 11
Bolognac 6 4 5 – 3 2
Funenc 1 3 2 6 7 4
aIn 2002 year; bData from Vlahovi}-Pal~evski et al15; cData from Bergman et al14
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In all cities and Funen area (Denmark), the men-
tioned drugs were within the DU90% segment, with the
exception of indometacin in Zagreb, Rijeka and Stock-
holm, piroxicam in Stockholm, and ketoprofen in Rije-
ka. The best NSAID profiles were found in Funen, Den-
mark and Stockholm, Sweden, whereas Bologna, Italy
had the worst profile, with Zagreb and Rijeka, Croatia
lying in between. The pattern recorded in Rijeka and
Zagreb was highly comparable for a small number of
drugs falling within DU95% segment (only three and
four drugs, respectively). In the present study, DU95%
instead of DU90% segment was used because in the City
of Zagreb three drugs accounted for a considerably less
than 90%, and four drugs for about 95% of the overall
NSAID utilization. Furthermore, Zagreb and Rijeka
were comparable by the predominance of diclofenac rel-
ative to other drugs according to DU95% and DU90%
proportion; high proportion of the high risk piroxicam;
and low proportion of the low risk ibuprofen in both cit-
ies. The high proportion of piroxicam and lowest propor-
tion of ibuprofen in DU95% segment appear to suggest
that evidence based medicine was not the leading im-
pact factor in prescribing these drugs.We stressed that
ibuprofen was only prescription drug during 2001 and
2002. Zagreb and Rijeka also showed similar patterns in
the cost for particular NSAIDs per DDD in DU95% and
DU90% segment, however, the mean costs for NSAIDs
per DDD beyond DU95% and DU90% differed signifi-
cantly. The introduction of rofecoxib to the Croatian
market contributed to the higher cost per DDD beyond
DU95% in Zagreb. The significant difference recorded
for both Zagreb and Rijeka as compared with other Eu-
ropean cities implied that in the latter, DU90% included
between six and eight drugs, along with a considerably
greater number of drugs being available on the mar-
ket14,15. In Zagreb, the COX-2 selective inhibitor rofeco-
xib was not included in DU95% segment, which is quite
conceivable due to its high price, thus being not in-
cluded in the List of Drugs approved by the Croatian In-
stitute of Health Insurance (CIHI) as well as because of
the controversy about the safety profile of COX-2 inhibi-
tors, reported in the studies published until May 200210.
In spite of the limitations related to DDD versus pre-
scribing daily dose (PDD), our cost analysis yielded
quite interesting information. Thus, the DDD cost for
NSAIDs was by half lower within than beyond DU95%
segment, suggesting that less expensive drugs tended to
be prescribed in Zagreb. However, it was not low risk
ibuprofen that appeared as the least expensive drug but
diclofenac in 2001 and ketoprofen in 2002.
Even considering all the limitations of DU methodol-
ogy (PDD may be higher or lower than DDD in particu-
lar settings, reimbursement systems, education, mar-
keting, pricing, demography, socioeconomic, morbidity
etc. differ among different countries), the results of the
present study indicate Zagreb to be one of the European
cities where the prescribing patterns of NSAIDs do not
follow their relative GI toxicity. Our results suggest that
other factors rather than evidence based medicine must
have predominantly influenced the prescribing of
NSAIDs in Zagreb during the past two years. This also
holds for other European cities, as reported by other
investigators14,15. Target education from independent
sources in the prescribing, dispensing and use of drugs
poses itself as a necessary measure to improve the qual-
ity of prescribing NSAIDs. The higher use of ibuprofen
and reduced use of piroxicam will improve the NSAID
profile in Zagreb.
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RAZINA EKONOMI^NOSTI PROPISIVANJA NESTEROIDNIH PROTUUPALNIH LIJEKOVA
U ZAGREBU
S A @ E T A K
Cilj istra`ivanja bio je ustanoviti potro{nju i kvalitetu propisivanja nesteroidnih protuupalnih lijekova (NSAIDs)
u Zagrebu. Iz podataka o broju i veli~ini pakovanja svakog NSAID s re`imom izdavanja na recept izdanih u 31 odno-
sno 32 javne ljekarne tijekom 2001. odnosno 2002. godine izra~unat je broj definiranih dnevnih doza (DDDs). Istra-
`ivani su oni NSAID koji ~ine 95% ukupne potro{nje svih NSAID, tzv. segment DU95%. Utvr|en je udio NSAID s
visokim (piroksikam), srednjim (diklofenak, naproksen, indometacin i ketoprofen) i niskim (ibuprofen) rizikom za
nastanak gastrointestinalnih nuspojava, tro{kovi za svaki NSAID unutar segmenta DU95% te tro{kovi po DDD.
^etiri NSAID ~ine segment DU95%: ibuprofen, diklofenak, ketoprofen i piroksikam. Tro{kovi po DDD su dvostruko
ni`i unutar segmenta DU95% u odnosu na NSAIDs izvan segmenta DU95%. Najskuplji NSAID unutar segmenta
DU95% je piroksikam, dok su najjeftiniji diklofenak u 2001. odnosno ketoprofen u 2002. godini. Propisivanje NSAID
u Zagrebu ne slijedi njihovu relativnu gastrointestinalnu toksi~nost.
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